Brief: Hls Therapeutics Announces Q3 Fiscal 2022 Financial Results
Nov 10 (Reuters) - Hls Therapeutics Inc HLS.TO :
* Q3 LOSS PER SHARE $0.14
* HLS THERAPEUTICS ANNOUNCES Q3 FISCAL 2022 FINANCIAL
RESULTS AND
RENEWAL OF NORMAL COURSE ISSUER BID
* QTRLY REVENUE WAS $15.7 MILLION COMPARED TO $15.1 MILLION
IN Q3
2021
* Q3 REVENUE VIEW $16.6 MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nCNW8zs6xa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease